Literature DB >> 339869

Physostigmine in mania.

K L Davis, P A Berger, L E Hollister, E Defraites.   

Abstract

Seven men and one woman with primary affective disorder, mania, were given a slow intravenous infusion of physostigmine salicylate. In six patients, mood and thought content changed from mania toward depression as evaluated by either a visual analog mood scale or the Pettersen scale. Two other patients, who were the only predominantly irritable manics in the study, demonstrated little change in their hostility, although one became somewhat depressed. These findings are consistent with earlier reports of suppression of manic symptoms after physostigmine infusion in some but not all patients with mania. The pharmacologic mechanism of physostigmine reversal of manic symptoms may be the direct result of increased cholinergic activity or a result of the effect of increased cholinergic activity on other brain neurotransmitters.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 339869     DOI: 10.1001/archpsyc.1978.01770250121012

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  22 in total

1.  Psychiatry-epitomes of progress: cholinergic hypersensitivity in patients with affective disorders.

Authors:  D S Janowsky
Journal:  West J Med       Date:  1981-02

2.  The prominent role of stimulus processing: cholinergic function and dysfunction in cognition.

Authors:  Maura L Furey
Journal:  Curr Opin Neurol       Date:  2011-08       Impact factor: 5.710

3.  Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.

Authors:  Maura L Furey; Wayne C Drevets
Journal:  Arch Gen Psychiatry       Date:  2006-10

Review 4.  The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited.

Authors:  Jordy van Enkhuizen; David S Janowsky; Berend Olivier; Arpi Minassian; William Perry; Jared W Young; Mark A Geyer
Journal:  Eur J Pharmacol       Date:  2014-08-05       Impact factor: 4.432

5.  The effects of alaproclate on the pupillary responses to tyramine, phenylephrine and pilocarpine in depressed patients.

Authors:  C Thompson; S A Checkley
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 6.  Acetylcholine and affective disorder.

Authors:  S S Leong; W A Brown
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

Review 7.  Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.

Authors:  Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  Depress Anxiety       Date:  2011-02-24       Impact factor: 6.505

Review 8.  Dopamine and depression.

Authors:  A S Brown; S Gershon
Journal:  J Neural Transm Gen Sect       Date:  1993

Review 9.  Bipolar disorder: candidate drug targets.

Authors:  Carlos A Zarate; Husseini K Manji
Journal:  Mt Sinai J Med       Date:  2008 May-Jun

10.  Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects.

Authors:  A S Gibbons; E Scarr; C McLean; S Sundram; B Dean
Journal:  J Affect Disord       Date:  2008-12-21       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.